Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic LeukemiaJohn C. Byrd, Susan O’Brien, Richard R. Furman et al.|New England Journal of Medicine|2013Cited by 2.2k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid LeukemiaJohn C. Byrd, Peter Hillmen, Paul M. Barr et al.|New England Journal of Medicine|2014Cited by 1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic LeukemiaJan A. Burger, Thomas J. Kipps, Alessandra Tedeschi et al.|New England Journal of Medicine|2015Cited by 1.6k
A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases.Samantha Jaglowski, John C. Byrd, Jeffrey A. Jones et al.|Journal of Clinical Oncology|2012Cited by 65
Combination of the Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 with bendamustine (B)/rituximab (R) (BR) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase Ib/II study.Susan O’Brien, Jennifer R. Brown, Jacqueline C. Barrientos et al.|Journal of Clinical Oncology|2012Cited by 36